Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline inc… Read more
Processa Pharmaceuticals Inc (PCSA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.597x
Based on the latest financial reports, Processa Pharmaceuticals Inc (PCSA) has a cash flow conversion efficiency ratio of -0.597x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.48 Million) by net assets ($5.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Processa Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Processa Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Processa Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Processa Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Concrete Engineering Products
KLSE:8435
|
-0.053x |
|
HF Co.
LSE:0EOI
|
-0.021x |
|
Pengana Capital Group Ltd
AU:PCG
|
0.058x |
|
Intraco Penta Tbk
JK:INTA
|
-0.008x |
|
JKN Global Media Public Company Limited
BK:JKN
|
-0.076x |
|
GR.SOU.COP. LS-01
F:E9E
|
N/A |
|
Millbank Mining Corp.
V:MILL
|
-0.172x |
|
PT Sumber Sinergi Makmur Tbk
JK:IOTF
|
0.172x |
Annual Cash Flow Conversion Efficiency for Processa Pharmaceuticals Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Processa Pharmaceuticals Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.70 Million | $-11.25 Million | -6.630x | -310.21% |
| 2023-12-31 | $4.99 Million | $-8.06 Million | -1.616x | -25.70% |
| 2022-12-31 | $7.47 Million | $-9.61 Million | -1.286x | -275.88% |
| 2021-12-31 | $25.49 Million | $-8.72 Million | -0.342x | -149.64% |
| 2020-12-31 | $22.94 Million | $-3.14 Million | -0.137x | +60.08% |
| 2019-12-31 | $8.01 Million | $-2.75 Million | -0.343x | +10.20% |
| 2018-12-31 | $9.70 Million | $-3.71 Million | -0.382x | +91.38% |
| 2017-12-31 | $373.16K | $-1.65 Million | -4.434x | -1106.31% |
| 2016-12-31 | $-1.98 Million | $-871.91K | 0.441x | 0.00% |
| 2015-12-31 | $-1.98 Million | $-871.91K | 0.441x | +119.75% |
| 2014-12-31 | $1.21 Million | $-2.70 Million | -2.231x | -46.86% |
| 2013-12-31 | $1.67 Million | $-2.54 Million | -1.519x | -106.37% |
| 2012-12-31 | $2.56 Million | $-1.89 Million | -0.736x | -187.76% |
| 2011-12-31 | $2.78 Million | $-710.00K | -0.256x | -- |